Introduction
The ongoing antigenic variability of influenza virus surface antigens remains a problem for the production of current commercial vaccines, which principally protect the host by inducing neutralizing antibodies to these antigens and are unable to induce strong mucosal or cellular immune responses. In particular, the cytotoxic T lymphocyte (CTL) response, which is directed against the nucleoprotein (NP) (Kees & Krammer, 1984 ; Parker & Gould, 1996 ; Yewdell et al., 1985) and other relatively conserved internal viral proteins implicated in virus replication and expressed early in infected cells, is essentially absent. In humans, the importance of this CTL response is not yet clearly defined, but studies suggest that it plays at least a co-operative role in virus clearance. In the Author for correspondence : Nicolas Escriou.
Fax j33 1 40 61 32 41. e-mail escriou!pasteur.fr absence of pre-existing strain-specific neutralizing antibody, protection against influenza virus infection in humans mediated predominantly by CTLs has been inferred (McMichael et al., 1983) and in immunosuppressed patients, cases of persistent influenza virus infections have been reported (McMinn et al., 1999 ; Rocha et al., 1991) . Moreover, the importance of a CTL response is supported by the existence of CTL escape mutants (Voeten et al., 2000) , indicating that during an epidemic season, a CTL response in humans is operating and applying selective pressure on circulating influenza virus strains. The role of the CTL response is more clearly demonstrated in the mouse model. For instance, it has been shown that reduction of virus load in the lungs and histological recovery correlate with specific CD8 + CTL responses (Allan et al., 1990 ; Topham & Doherty, 1998) and that adoptive transfer of CTL clones activated in vitro can provide protection against influenza virus in mice (Graham & Braciale, 1997 ; Taylor & Askonas, 1986 ).
Efforts to develop approaches that would fortify the immune response by inducing CTLs against the influenza virus NP, using systems that express whole NP, have received particular attention. Immunization of mice with influenza virus NP expressed by recombinant vaccinia virus (Endo et al., 1991 ; Lawson et al., 1994 ; Stitz et al., 1990) , fowlpox virus (Webster et al., 1991) , Semliki Forest virus (SFV) (Zhou et al., 1995) or Sindbis virus (SIN) (Tsuji et al., 1998) has been shown to induce immune responses that, in some cases, confer at least partial protection.
An alternative to these approaches, gene immunization, is based on the inoculation of DNA expression vectors that contain gene sequences encoding a foreign protein. Immunization with naked DNA vectors encoding the influenza virus NP has been shown to induce antibodies, cellular responses and protection against both homologous and crossstrain challenge infection by influenza A virus variants (Bot et al., 1996 ; Ulmer et al., 1993 Ulmer et al., , 1998 . The advantages of DNA immunization include ease of production, purification and administration of the vaccine and a long-lasting immunity. This long-lived immunity lasts for more than 1 year in the mouse model and is probably due to the long-term persistence and expression of the injected DNA (Wolff et al., 1992) . For this very reason, some questions remain from a clinical standpoint as to the potential risk of DNA sequence integration into the host genome, although preliminary studies in animals have not shown integration events to lead to insertional mutagenesis (Nichols et al., 1995) .
To avoid these potential hazards, RNA has been proposed as the expression vector ; however, development of this approach faces new problems posed by the short intracellular half-life of RNA and its degradation by ubiquitous RNases. Initial attempts used mRNA to induce immune responses ; the RNA was administered either intramuscularly (Conry et al., 1995) by gold particle-coated gene gun delivery (Qiu et al., 1996) or by liposome-encapsulated injection to protect the RNA during administration (Martinon et al., 1993) . To further improve delivery of these molecules, encapsidated selfreplicating RNAs or replicons derived from the genomes of positive-stranded RNA viruses have been developed. In such systems, the structural protein sequences of the RNA genome are substituted for heterologous sequences that express a foreign protein, while the non-structural protein genes are retained ; these replicons are capable of undergoing one round of replication.
The genomes of the alphaviruses SFV and SIN have been manipulated in this manner to allow the expression of foreign proteins (Frolov et al., 1996) . Packaging of such replicons stabilizes the RNA molecules and injection of the resulting virus-like particles induces an array of immune responses against the given protein. Similarly, the capsid coding sequences of poliovirus positive-sense RNA have been deleted to permit the expression of foreign proteins (Choi et al., 1991 ; Percy et al., 1992) and, when packaged into virus-like particles, this replicon can induce immune responses after injection into mice transgenic for the poliovirus receptor (Moldoveanu et al., 1995 ; Porter et al., 1997) .
In this study, we evaluated the ability of recombinant replicons to induce both humoral and cellular immune responses when injected in the form of naked RNA, arguing that packaging these vectors is unnecessary, since their replicative nature alleviates the need for large quantities of input RNA. In the case of recombinant SFV vectors encoding the haemagglutinin and NP molecules of influenza A virus, the injection of naked RNA has been found to induce specific antibodies (Dalemans et al., 1995 ; Zhou et al., 1994) . We showed here that two recombinant replicons, one derived from the SFV genome and the other from the poliovirus genome, which both encode the internal influenza A virus NP protein in place of the structural proteins, can elicit humoral responses after injection of naked RNA. Moreover, injection of naked rSFV-NP replicon RNA was found to induce a CTL response that was specific for the immunodominant epitope of the influenza virus NP and to reduce virus load in the lungs of infected mice challenged with a mouse-adapted influenza virus to the same extent as that seen using the DNA immunization technique.
Methods
Cells and viruses. HeLa Young and BHK-21 cells were grown at 37 mC in complete Dulbecco's modified Eagle's medium (DMEM) containing 1 mM sodium pyruvate, 4n5 mg\ml -glucose, 100 U\ml penicillin and 100 µg\ml streptomycin and supplemented with 5 % heatinactivated foetal calf serum (FCS) (TechGen). EL4 (mouse lymphoma, H-2 b ) and P815 (mouse mastocytoma, H-2 d ) cells were maintained in complete RPMI 1640 medium containing 10 mM HEPES, 50 µM β-mercaptoethanol, 100 U\ml penicillin and 100 µg\ml streptomycin and supplemented with 10 % FCS.
Mouse-adapted influenza A\PR\8\34(ma) virus (H1N1) was derived from serial passage of pulmonary homogenates of infected mice to naive mice, as described previously (Oukka et al., 1996) . Subsequent virus stocks were produced by a single allantoic passage in 11-day-old embryonated hen's eggs, which did not affect virus pathogenicity for mice.
Construction of the pCI-NP expression vector. Viral genomic RNA was extracted from lung homogenates of influenza A\PR\8\34(ma) virus-infected mice using 5 M guanidium isothiocyanate and phenol and reverse-transcribed into cDNA. Next, the sequences encoding influenza virus NP, including a SalI site before the initiation codon, were amplified by PCR using Pwo DNA polymerase (Roche). The resulting DNA fragment was cloned between the SalI and the Klenow-treated SacI sites of plasmid pTG186 (Kieny et al., 1986) . Based on the consensus sequence, which can be obtained from the authors upon request, plasmid pTG-NP82 was reconstructed. A silent mutation was introduced at codon 107 (E, GAG GAA), which destroyed an EcoRI site for the purpose of the subsequent cloning steps. An additional mutation at codon 277 (Pro Ser) was present in all NP sequences used in this study ; this mutation does not directly affect the major histocompatibility complex (MHC) class I-restricted immunodominant epitope of interest, NP366 (aa 366-374). The SalI-SmaI fragment of pTG-NP82 was then inserted BHDI between the SalI and SmaI sites of expression plasmid pCI (Promega) to yield plasmid pCI-NP.
Construction of plasmids for the in vitro transcription of recombinant replicons. pSFV-NP was constructed by the insertion of the NP gene, derived from pTG-NP82, into the SmaI site of pSFV1, which contains a subgenomic cDNA of SFV downstream from the SP6 RNA polymerase promoter (Liljestro$ m & Garoff, 1991) .
Plasmids containing poliovirus cDNAs with P1 deletions and substitutions were derived from plasmid pT7-PV1-52, which contains the full-length poliovirus type I (Mahoney) infectious cDNA downstream of the phage T7 promoter (Marc et al., 1989) . Plasmid p∆P1-E contains a subgenomic poliovirus cDNA in which nt 746-3366 were replaced by a SacI-XhoI-SalI polylinker (GAGCTCGAGCTGTCGAC). In addition, the SalI site of the pBR322 vector backbone of p∆P1-E was removed by digestion with EagI\EcoN1, Klenow-filling and ligation.
Plasmid p∆P1-E-NP was constructed by the in-frame insertion of sequences encoding the influenza A\PR\8\34(ma) virus NP, derived from pTG-NP82 after digestion with NcoI\MfeI and treatment with the Klenow fragment, into the Klenow-filled XhoI site of p∆P1-E.
In vitro transcription of plasmid DNA. The poliovirus and SFV genome-derived plasmids were linearized with EcoRI and SpeI, respectively, and transcribed using the RiboMAX Large Scale RNA Production systems (Promega) (T7 polymerase for the former, SP6 polymerase for the latter), according to the manufacturer's instructions. SFV transcripts were capped during transcription using 3 mM of cap analogue (Epicentre Technologies). For in vivo studies, reaction mixtures were treated with RQ1 DNase (1n5 U\µg DNA) (Promega) for 20 min at 37 mC, extracted with phenol-chloroform, precipitated first in ammonium acetate-isopropyl alcohol, then in sodium acetate-isopropyl alcohol and resuspended in endotoxin-free PBS (Life Sciences). For in vitro translation studies, reaction mixtures were processed in the same way, but precipitated once with sodium acetate-isopropyl alcohol and resuspended in dH # O. Rabbit reticulocyte lysate in vitro translation. RNA transcribed in vitro was translated using the in vitro Flexi Rabbit Reticulocyte Lysate system (Promega) supplemented with 0n8 mCi\ml [$&S]methionine (1000 Ci\mmol ; Amersham), 80 mM KCl and 20 % HeLa cell S10 extract (a kind gift from Lisette Cohen, Institut Pasteur, Paris, France). Reaction mixtures were incubated for 3 h at 30 mC, treated with 100 µg\ml RNase A in 10 mM EDTA for 15 min at 30 mC and finally analysed by 12 % SDS-PAGE and autoradiography on Kodak X-OMAT film.
RNA transfection. Transfection of RNA into HeLa or BHK-21 cells was performed by electroporation using an Easyject plus electroporator (Equibio). Briefly, 8i10' cells were trypsinized, washed twice, resuspended in 400 µl ice-cold PBS and electroporated in the presence of 16 µg RNA or DNA using a single pulse (240 V, 900 µF, maximum resistance) for HeLa cells or a double pulse (1200 V, 25 µF, 156 Ω then 150 V, 2100 µF, 99 Ω) for BHK-21 cells in 0n4 cm electrode gap cuvettes. Cells were immediately transferred into DMEM supplemented with 2 % FCS and distributed into four 35 mm diameter tissue culture dishes.
Analysis of RNA replication. At different time intervals posttransfection, cytoplasmic RNA was prepared using standard procedures (Sambrook et al., 1989) . After denaturation, RNA samples were spotted onto a nylon membrane (Hybond-N, Amersham), hybridized with a $#P-labelled RNA probe complementary to nt 3417-4830 of poliovirus RNA, essentially as described previously (Marc et al., 1989) , and exposed on a Storm phosphorimager (Molecular Dynamics).
Analysis of influenza virus NP expression in RNA-transfected cells. Influenza A\PR\8\34 virus-infected or RNA\DNA-transfected cells were metabolically labelled with [$&S]methionine (50 µCi\ml) (1000 Ci\mmol ; Amersham) for 2 h at times of peak expression. Next, cells were washed in PBS and lysed with 50 mM Tris-HCl, pH 7n5, 150 mM NaCl, 1 mM EDTA, 1 % NP40 and 0n5% protease inhibitor cocktail (Sigma). Cell extracts were then immunoprecipitated overnight at 4 mC in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0n1 % deoxycholate, 0n1 % SDS, 0n5 % NP40 and 0n5 % Protease Inhibitor cocktail) in the presence of protein A-Sepharose beads (Amersham) with rabbit antibodies raised against influenza A\PR\8\34 virus. The immunoprecipitates, washed in RIPA buffer and eluted in Laemmli sample buffer at 65 mC, were analysed by SDS-PAGE and visualized by autoradiography on Kodak X-OMAT film.
Immunizations. Male C57BL\6 mice (IFFA CREDO) 7 to 8 weeks of age were injected intramuscularly with 100 µl PBS (50 µl in each tibialis anterior muscle) containing 50 µg of plasmid DNA, 25 µg of poliovirus replicon RNA or 10 µg of capped SFV replicon RNA. Booster injections were administered at three or four week intervals. DNA used for injection was prepared using the Nucleobond Megaprep kit, followed by extraction steps with Triton X-114 and phenol-chloroform and tested for the absence of endotoxin ( 100 U\mg), as measured with the QCL-1000 Endotoxin kit (BioWhittaker). RNA preparations were analysed before and after injection by agarose gel electrophoresis to verify the absence of degradation.
Antibody titre. Blood from mice was collected 1 week before immunization and 3 weeks after each injection. Serial dilutions of pooled serum samples were used to determine NP-specific antibody titres by ELISA using 0n5 µg of detergent-disrupted influenza A\PR\8\34 virus per well as antigen.
Cytotoxicity assay. Spleen cells were collected 3 weeks after the last immunization and seeded into upright T75 flasks at 2i10' cells\ml in complete RPMI 1640 supplemented with 10 % FCS, non-essential amino acids, 1 mM sodium pyruvate and 2n5 % concanavalin A. They were then re-stimulated for 7 days with 10' syngeneic spleen cells\ml, which had been pulsed for 3 h with 10 µM NP366 peptide (ASNENMETM, Neosystem), washed and irradiated (2500 rads). Cytotoxic activity of the re-stimulated effector cells was measured using a standard &"Cr-release cytotoxicity assay, essentially as described previously (Escriou et al., 1995) . EL4 and P815 target cells were pulsed or not with NP366 peptide (10 µM) during &"Cr-labelling. Spontaneous and maximal release of radioactivity were determined by incubating cells in medium alone or in 1 % Triton X-100, respectively. The percentage of specific &"Cr release was calculated as (experimental release kspontaneous release)\(maximal releasekspontaneous release)i100.
Challenge infection of mice with influenza A/PR/8/34(ma) virus. At 1 or 3 weeks after the third immunization, mice were lightly anaesthetized with 100 mg\kg ketamine (Merial) and challenged intranasally with 100 p.f.u. (0n1 LD &! ) influenza A\PR\8\34(ma) virus in 40 µl PBS. Mice were sacrificed 7 days after challenge infection and lung homogenates were prepared and titred for virus on MDCK cell monolayers in a standard plaque assay. Statistical analyses were performed on the log of the virus titres, measured for individual mice using the Student t-test with the assumptions used for small samples (normal distribution of the variable, same variance for the populations to be compared).
Results

Production of recombinant replicons derived from the SFV and poliovirus genomes
For the production of SFV genome-derived replicons, the sequences encoding the mouse-adapted influenza A\PR\8\34 BHDJ M. Vignuzzi and others M. Vignuzzi and others to 3366 of the P1 region, which encodes the structural proteins, were deleted from pT7-PV1-52, which contains the complete infectious cDNA of poliovirus type 1 Mahoney downstream of the T7 bacteriophage promoter. Deleted sequences were replaced by a SacI-XhoI-SalI polylinker (not shown to scale), whereas sequences encoding the nine C-terminal amino acids of VP1 comprising the optimal sequence for in cis cleavage by the 2A protease were retained, thus yielding plasmid p∆P1-E. Plasmid p∆P1-E-NP was constructed by the insertion of sequences encoding the influenza A/PR/8/34(ma) virus NP (hatched box) in-frame with the remainder of the poliovirus polyprotein sequences behind the poliovirus initiation codon. Extra amino acid residues of the NP-VP1* fusion protein derived from the poliovirus sequences are shown on either side in single-letter format. The Y-G cleavage site of proteinase 2A pro is indicated by an arrow.
virus NP were inserted into the polylinker of the SFV expression vector pSFV1 (Liljestro$ m & Garoff, 1991) downstream of the 26S subgenomic promoter in place of sequences encoding the SFV structural proteins, as described in Methods (Fig. 1 a) . SP6 RNA polymerase transcription of pSFV-NP linearized with SpeI allowed the synthesis of capped positivesense recombinant RNAs capable of initiating a replication cycle when transfected into cells (data not shown).
For the production of poliovirus genome-derived replicons, the plasmid vector p∆P1-E was first constructed, in which the capsid protein-coding sequences of P1 were substituted with a polylinker, such that sequences corresponding to an optimal cleavage site for the 2A protease, consisting of the nine Cterminal amino acids of VP1 and the first amino acid of 2A (as defined by Hellen et al., 1992) , were maintained (Fig. 1 b) . The sequences coding for the influenza virus NP were then inserted upstream of this reconstituted cleavage site and in-frame with the rest of the sequences encoding the poliovirus polyprotein to yield plasmid p∆P1-E-NP (Fig. 1 b) .
The recombinant RNAs, r∆P1-E and r∆P1-E-NP, derived from in vitro transcription with T7 RNA polymerase of p∆P1-E and p∆P1-E-NP-linearized DNAs were translated in vitro in rabbit reticulocyte lysates. As shown in Fig. 2 , the repliconencoded polyproteins were properly cleaved to express the non-structural proteins necessary for RNA amplification (as shown by the end products of cleavage), such as the 2A, 3CD, 2BC and 2C proteins. In particular, correct in cis cleavage of the reconstituted VP1-2A site by the 2A protease was observed. For the subgenomic replicon r∆P1-E, however, this cleaved product migrated as a doublet, which could be explained as a mixture of properly cleaved product and uncleaved VP1*-2A fusion protein containing the 13 amino acid residues of the reconstituted cleavage site and polylinker. It could be argued that the very short stretch of amino acids before the cleavage site was too short to permit 100 % cleavage. For the recombinant replicon r∆P1-E-NP, such uncleaved product, which would have appeared as a 72 kDa NP-VP1*-2A fusion protein, was barely visible, suggesting that the addition of the NP sequences alleviated the spatial restriction seen in the previous case. Expression of the properly cleaved NP-VP1* fusion protein was therefore revealed by the presence of a band with the expected molecular mass of 56 kDa (Fig. 2) .
Replicative characteristics of poliovirus genomederived replicons r∆P1-E and r∆P1-E-NP
Since the influenza virus NP has been shown to associate non-specifically with RNAs (Kingsbury et al., 1987 ; Yamanaka et al., 1990) , an interaction with the poliovirus RNA could hypothetically affect overall replication efficiency. Therefore, synthetic RNA transcripts of r∆P1-E and r∆P1-E-NP, as well as parental rT7-PV1-52, were transfected into HeLa cells and total cytoplasmic RNA was extracted at various times post-transfection. Hybridization after slot blotting using a radiolabelled riboprobe complementary to nt 3417-4830 of poliovirus RNA revealed efficient replication of all RNAs (Fig. 3) . Similar results were obtained after transfection of L929 murine cells (data not shown). In our current studies, cells were transfected by electroporation, which was more efficient than the classic DEAE-dextran technique ( 90 % transfection efficiency). Under these conditions, all three RNA species induced cytopathic effects, regardless of the presence or absence of capsid proteins, and resulted in the general destruction of the cell monolayer (data not shown). Taken together, these results illustrated that the insertion of sequences encoding the influenza virus NP had no negative effects on RNA replication. 
Expression of influenza virus NP by recombinant SFV and poliovirus genome-derived replicons
Nucleoprotein expression was analysed by immunoprecipitation (using antibodies against influenza A\PR\8\34 virus) of cytoplasmic extracts from cells transfected with SFV or poliovirus genome-derived replicons or plasmid DNA, or infected with influenza A\PR\8\34 virus, as described in Methods. Cells were pulse-labelled with [$&S]methionine for 2 h prior to harvest at times of peak expression, as determined in preliminary experiments. As shown in Fig. 4 (a) , a protein with an apparent molecular mass of 54 kDa was specifically immunoprecipitated from extracts of cells transfected with rSFV-NP (Fig. 4 a, lane 2) and co-migrated with the NP produced by 293 cells infected with influenza A\PR\8\34 virus (Fig. 4 a, lane 1) . No immunoreactive proteins could be detected from the mock-transfected cells or from cells transfected with replicon RNA derived from the empty vector pSFV1.
Similarly, transfection of HeLa cells with the recombinant replicon r∆P1-E-NP (Fig. 4 b, lane 5) resulted in high levels of NP-related protein expression. The majority of NP expressed by the poliovirus genome-derived replicon migrated slightly slower than the native form of NP expressed by pCI-NP DNAtransfected cells (Fig. 4 b, lane 3) . This difference in molecular mass accounted for the additional amino acid residues of the NP-VP1* fusion protein and was consistent with the fact that proteolytic processing of the poliovirus polyprotein occurred at the reconstituted VP1*-2A cleavage site. Interestingly, the presence of bands of a smaller molecular mass (Fig. 4 b, lane 5) suggested that the NP produced may have been cleaved, in part, by one of the poliovirus proteases (2A or 3C). Examination of the NP sequences for such cleavage sites (Y-G for 2A protease or Q-G for 3C protease) confirmed this possibility ; nevertheless, these potential cleavage by-products remained a minority. Thus, both SFV and poliovirus genomederived recombinant replicons were shown to direct efficient expression of the influenza virus NP in transfected cells.
Induction of NP-specific antibodies after immunization with recombinant rSFV-NP and r∆P1-E-NP replicons
In order to establish the feasibility of using naked replicon injection to elicit a heterospecific CTL response, we first determined the conditions of RNA injection required to obtain an antibody response comparable to that observed after one injection of plasmid DNA, which in published literature was shown to be sufficient to induce a CTL response (Ulmer et al., 1993) . To this end, naked RNA or DNA was administered BHEC Naked RNA vaccines against influenza A virus Naked RNA vaccines against influenza A virus Fig. 5 . Anti-NP antibody response to immunization with naked RNA. C57BL/6 mice were immunized two or three times at four week intervals with 50 µg of plasmid DNA (pCI or pCI-NP), 10 µg of SFV genomederived replicon RNA (rSFV or rSFV-NP) or 25 µg of poliovirus genomederived replicon RNA (r∆P1-E or r∆P1-E-NP). Sera were collected before (0) the first (1), second (2) or third (3) injection or after. Titres are represented as the reciprocal of the highest dilution of pooled sera for a given group of five or six mice giving an optical density measurement at 450 nm equal to three times that of background levels in a direct ELISA test using purified split influenza A/PR/8/34 virions as antigen. Data from one experiment representative of two are shown.
intramuscularly at monthly intervals (one, two or three times) to C57BL\6 mice and the specific anti-NP antibody response was examined by ELISA, as described in Methods.
As shown in Fig. 5 , one injection of 10 µg of naked rSFV-NP RNA induced serum antibodies against influenza virus NP, although the specific ELISA titres were reproducibly lower than those obtained after one injection of 50 µg of pCI-NP DNA. At 3 weeks after a booster injection, a strong increase in the anti-NP antibodies in the sera of rSFV-NP-injected mice was observed, reaching a level comparable to that obtained after two injections of pCI-NP DNA. Three injections of 25 µg of naked r∆P1-E-NP RNA proved necessary to raise NPspecific antibodies to levels equal to or slightly higher than those achieved by one injection of plasmid pCI-NP DNA. Thus, these findings showed that poliovirus replicons were immunogenic when injected as naked RNA, although less so when compared to the SFV replicons.
Induction of an NP-specific CTL response after injection of recombinant SFV replicon as naked RNA
In order to evaluate whether recombinant rSFV-NP and r∆P1-E-NP injected as naked RNA were able to induce specific CTLs directed against the dominant H-2D b -restricted epitope NP366, C57BL\6 mice were injected intramuscularly either once or twice with 10 µg of rSFV-NP RNA, three times with 25 µg of r∆P1-E-NP RNA or once with 50 µg of pCI-NP DNA as a positive control. This immunization schedule was defined according to the previously determined anti-NP antibody response and based on the observation that one injection of plasmid DNA was sufficient to induce a detectable NP-specific CTL response at levels just below those of mice having recovered from sub-lethal influenza A\PR\8\34(ma) virus infection (data not shown). Splenocytes from immunized mice were harvested 3 weeks after the last injection, stimulated in vitro with peptide NP366 and tested for cytolytic activity 7 days later using a classic chromium-release assay, as described in Methods. Spleen cell cultures initiated from mice injected once with either rSFV-NP RNA or pCI-NP DNA (Fig. 6 a) specifically lysed EL4 cells loaded with peptide NP366. A much higher level of cytolytic activity was detected for spleen cells of mice that had received a booster injection of rSFV-NP RNA (Fig. 6 a) . In all cases, no lysis was observed with stimulated splenocytes from control naive mice or from mice that were immunized with control vectors without the NP M. Vignuzzi and others M. Vignuzzi and others Fig. 7 . Naked RNA immunization with replicon rSFV-NP confers protection against influenza virus challenge. C57BL/6 mice (five or six per group) were immunized three times at 3 week intervals with either 10 µg of rSFV or rSFV-NP replicon RNA or 50 µg of pCI or pCI-NP plasmid DNA. A week after the last injection, mice were challenged with 10 2 p.f.u. (0n1 LD 50 ) of mouse-adapted influenza A/PR/8/34 virus and virus titres in the lungs were determined 7 days post-challenge infection, as described in Methods. Virus loads in mice injected with each NP-encoding vector were significantly lower than for mice injected with the corresponding empty vector (P 0n001 ; Student's t-test). The mean (open circles)pSD of each group is shown. Data from one experiment representative of six are shown.
sequences (Fig. 6, hatched lines) , nor was any lysis detected on syngeneic targets not charged with peptide (Fig. 6 b) . Finally, for all effector populations, lysis of allogenic P815 target cells (H-2 d ) remained at background levels regardless of whether or not they were incubated with peptide (data not shown), indicating that the cytolytic activity was H-2-restricted and was thus likely to derive from MHC-I-restricted CD8 + T cell effector cells. In contrast, splenocytes from r∆P1-E-NP-injected mice failed to lyse either of the EL4 targets, despite maintaining the same immunization schedule (i.e. three injections of 25 µg of RNA) that was found to induce NP-specific antibodies. Three injections of 100 µg of r∆P1-E-NP RNA also failed to induce a detectable CTL response (data not shown).
Protective immunity in vivo
Previous studies have found that CTLs directed against the influenza virus NP and induced by naked DNA immunization were protective against a challenge infection with influenza virus (Bot et al., 1996 ; Ulmer et al., 1993) . To determine whether the CTL responses induced by naked RNA immunization with SFV genome-derived replicons could also contribute to protection by reducing virus titre in the lungs, C57BL\6 mice were injected three times with either rSFV-NP RNA or pCI-NP DNA and challenged with a sublethal dose of the homologous influenza A\PR\8\34(ma) virus (10# p.f.u.) 1 or 3 weeks thereafter. Virus load in the lungs was evaluated 7 days after challenge by plaque assay on MDCK cells. In all six studies, such as the one shown in Fig. 7 , immunization with either naked SFV RNA or naked DNA encoding the influenza virus NP lowered virus lung titres by one to two logs. The observed reduction of virus loads after injection of each NP-coding molecule as compared to the respective blank vector was found to be significant by the Student t-test (P 0n001). It is worth noting that although the drop in virus titre was moderate, which would correlate with the high virulence of our mouse-adapted virus strain (LD &! was 10$ p.f.u. for C57BL\6 mice), the reduction in titre achieved with naked RNA immunization was as efficient as that obtained with naked DNA immunization.
Discussion
The principal aim of this study was to explore and evaluate the feasibility of adapting standard naked DNA immunization protocols for naked RNA immunization using positivestranded RNA virus genomes that have structural proteincoding sequence deletions and are capable of a single round of replication, as vaccine vectors against influenza virus.
The genome of poliovirus is a good candidate for naked RNA immunization because encapsidated subgenomic poliovirus replicons expressing viral, bacterial and tumour antigen have already been described (Ansardi et al., 1994 ; Choi et al., 1991 ; Porter et al., 1997) . Furthermore, live recombinant polioviruses expressing simian immunodeficiency virus proteins are being developed as prototypes for an AIDS vaccine that elicits humoral and cellular immune responses in nonhuman primates (Crotty et al., 1999) . We showed here that when administered as naked RNA, a recombinant poliovirus replicon, r∆P1-E-NP, engineered to express the influenza virus NP was able to induce NP-specific antibodies in mice after three injections, which suggested that the replicon did replicate at least to some extent in vivo. This was further supported by the fact that a neutralizing antibody response against the poliovirus capsid proteins was elicited after injection with the full-length poliovirus genome in the form of naked RNA into C57BL\6 mice, which do not express the poliovirus receptor (data not shown). However, no CTL response was detected towards the immunodominant epitope of the influenza virus NP in C57BL\6 mice injected with r∆P1-E-NP.
Firstly, this lack of CTL response could be due to the possibility that the poliovirus genome replicates poorly in BHEE murine cells in vivo, particularly in myocytes, if these are indeed the site of protein expression, after intramuscular naked nucleic acid immunization (Corr et al., 1999) . Secondly, there is question as to whether or not the MHC-I-restricted NP366 peptide was properly presented by r∆P1-E-NP-transfected cells. It was shown that the protein secretion pathway is altered by poliovirus proteins 2B and 3A and recent evidence by Kirkegaard and colleagues has shown that 3A protein expression was responsible for strong inhibition of MHC-Idependent antigen presentation in poliovirus-infected cells (Deitz et al., 2000 ; Doedens & Kirkegaard, 1995) .
However, Mandl et al. (1998) have demonstrated that a CTL response can be induced in mice transgenic for the poliovirus receptor by a recombinant poliovirus containing sequences that encode the H-2 b -restricted CTL epitope of chicken ovalbumin. In this situation, the genome of the virus entered cells by infection rather than by uptake of injected naked RNA and multiple cycles of replication and re-infection of neighbouring cells were possible. Therefore, the inability to detect a CTL response may be due to differences in the number or type of cells receiving replicon RNA, levels of expression or route of immunization. In vitro antigen presentation assays are being developed to determine if NP peptide presentation does indeed occur in cells replicating the r∆P1-E-NP recombinant replicon.
Alternatively, the CTL response induced by the poliovirus recombinant replicon might be skewed towards another peptide, e.g. one of the poliovirus non-structural proteins that could be hypothetically dominant to the NP peptide, in C57BL\6 mice. Although sequences corresponding to the H-2D b epitope-binding motif are found throughout the proteins encoded by the poliovirus vector, there is no information currently available on whether these are the targets of a CTL response in H-2 b mice. A means to clarify this issue would be to examine the CTL response in H-2 d mice, for which the immunodominant epitope of the influenza virus NP is known, since it is unlikely that the same phenomenon would be repeated.
Finally, it is well accepted that the strong immunogenicity of DNA vaccines is a consequence of long-lasting antigen expression together with the adjuvant effect of short noncoding immunostimulatory sequences centred around unmethylated CpG motifs in the plasmid DNA backbone itself (Sato et al., 1996) . In the case of the highly effective naked RNA immunization with SFV replicons, it has been suggested that virus-like RNA replication could provide an adjuvant effect by triggering a series of ' danger signals ' which in turn would activate the innate immune system of the host . It is tempting to speculate that poliovirus could block, or at least inhibit, this process by an as yet unknown mechanism, thus resulting in a poorly immunogenic replicon that is able to avoid detection by the host immune system.
Injection of naked RNA from the recombinant rSFV-NP replicon designed to express the influenza virus NP proved to be effective at inducing anti-NP antibodies after two injections ; antibody titres were at levels comparable to those obtained by one injection of NP-encoding plasmid DNA. Induction of antibodies specific for an influenza virus protein by this type of vector when administered as naked RNA has already been described (Dalemans et al., 1995 ; Zhou et al., 1994) . Recently, using LacZ as a model tumour antigen for cancer therapy, Ying et al. (1999) have shown that injection of naked recombinant SFV RNA can elicit an antibody response, activate CD8 + T cells to release interferon-γ and protect from tumour challenge. Here, we showed that the injection of naked recombinant rSFV-NP RNA could induce, in addition to antibodies, CTLs that target the NP366 epitope in a response that was found to be comparable to that induced by plasmid DNA. Furthermore, we showed that in a virus challenge model using a mouseadapted strain of influenza virus, RNA immunization worked as well as DNA immunization in the degree of protection conferred, as measured by reduction of virus load in the lungs. It will be interesting to determine whether even greater protection is conferred after challenge with less virulent strains of mouse-adapted influenza virus and to evaluate the role of anti-NP CTLs induced by naked RNA immunization against a heterologous influenza virus of the same or a different subtype.
